Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified class period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the sales stall to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Rocket Pharmaceuticals is facing a securities class action lawsuit alleging misleading safety disclosures related to its RP-A501 gene therapy program, which has resulted in significant stock price decline following a serious adverse event [1][3]. Company Overview - Rocket Pharmaceuticals, based in Cranbury, New Jersey, specializes in developing gene therapies for rare diseases [2]. Legal Allegations - The lawsuit claims that Rocket Pharmaceuticals did not inform investors about a significant protocol change involving a new immunomodulatory agent before a serious adverse event occurred, leading to a clinical hold by the FDA [3]. - Following the disclosure of a patient death during the trial, Rocket Pharmaceuticals' stock plummeted nearly 37%, dropping from $6.27 on May 23, 2025, to $2.33 on May 27, 2025 [3]. Investor Information - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may be eligible for recovery, with a lead plaintiff application deadline set for August 11, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentations regarding its capital allocation and sales growth of its product Nexplanon during the class period from November 3, 2022, to April 30, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit claims that despite acquiring Dermavant for $1.2 billion, Organon assured investors it would maintain its dividend as its top capital allocation priority, which was later shifted to debt reduction [2][3]. - Allegations include failure to disclose risks related to Nexplanon, leading to overestimated sales growth projections and the likelihood of not achieving a $1 billion milestone payment from Merck & Co. [4]. Group 2: Financial Impact - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, causing its stock price to drop by approximately 27%, from $12.93 to $9.45 per share [5].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors regarding the monitoring of cost trends related to the Medicaid "redetermination" process and assured that premium rates were sufficient to cover rising costs [4]. - It was revealed that the redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, and lowered EPS guidance for 2024 from $37.20 to $33.00, or 11.3% [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for failing to disclose significant accounting irregularities related to its acquisition of Lugano Holdings, which may have distorted financial results during the Class Period [1][3]. Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut, which acquired a majority interest in Lugano Holdings, Inc. in 2021 for an enterprise value of $256 million [2]. Legal Allegations - The lawsuit alleges that during the Class Period, Compass did not disclose that: - Lugano violated applicable accounting rules and industry practices in fiscal 2024 [3]. - Lugano's 2024 financial results were artificially distorted due to these accounting irregularities [3]. - Compass failed to implement effective internal controls over its financial reporting [3]. Investor Information - Investors who purchased Compass securities during the Class Period have until July 8, 2025, to seek appointment as a lead plaintiff representative of the class [2].

Core Viewpoint - Aflac Inc. is under investigation for potential breaches of fiduciary duty and corporate governance failures related to a recent cybersecurity breach that may have compromised sensitive personal data of customers and employees [1][2][3] Group 1: Cybersecurity Breach - On June 12, 2025, Aflac disclosed that unauthorized actors accessed its U.S. systems, potentially compromising personal data including Social Security numbers, health records, and insurance claim information [2] - The company is currently assessing the full scope of the data exposure resulting from the breach [2] Group 2: Investigation Details - Berger Montague is evaluating whether Aflac's officers and directors failed to implement adequate cybersecurity protocols and whether they provided timely and accurate disclosures regarding the breach [3] - The investigation will also consider if there was a breach of the duty of oversight by Aflac's leadership [3]

Core Viewpoint - A securities class action lawsuit has been filed against Civitas Resources, Inc. for failing to disclose significant operational challenges during the Class Period from February 27, 2024, to February 24, 2025 [1][3]. Group 1: Company Performance - Civitas reported Q4 and full-year 2024 revenue of $1.29 billion, missing consensus estimates by $3.44 million, and non-GAAP earnings per share of $1.78 for the quarter, missing estimates by $0.21 per share [4]. - The company reported a net income of $151.1 million, or $1.57 per share, compared to $302.9 million, or $3.23 per share, in the same quarter of the previous year [4]. - Civitas announced a 10% reduction in its workforce and the termination of its Chief Operating Officer and Chief Transformation Officer [5]. Group 2: Market Reaction - Following the announcement of disappointing financial results and operational challenges, Civitas's stock price fell by $8.95 per share, or 18%, closing at $40.35 per share on February 25, 2025 [6]. Group 3: Legal Context - Investors who purchased Civitas securities during the Class Period have until July 1, 2025, to seek appointment as lead plaintiff in the class action lawsuit [2].

Core Viewpoint - A securities class action lawsuit has been filed against Open Lending Corporation for misrepresentation and failure to disclose significant financial issues during the Class Period from February 24, 2022, to March 31, 2025 [1][3]. Company Overview - Open Lending Corporation is headquartered in Austin, Texas, and provides loan services to auto lenders through a cloud-based auto lending protection platform [2]. Allegations - The lawsuit claims that Open Lending misrepresented its risk-based pricing models and profit share revenue, failed to disclose the devaluation of its 2021 and 2022 vintage loans, and misrepresented the underperformance of its 2023 and 2024 vintage loans [3]. Financial Disclosure - On March 17, 2025, Open Lending announced it would delay its Annual Report for 2024 due to issues with accounting and profit share revenue, leading to a 9% drop in share price to $3.91 [4]. - The company reported a quarterly revenue of negative $56.9 million for Q4 2024, attributed to an $81.3 million reduction in estimated profit share revenues due to heightened delinquencies and defaults on loans from 2021 to 2024 [5]. - The decline in estimated profit share was linked to the deterioration of 2021 and 2022 vintages, underperformance of 2023 and 2024 vintages, and continued elevated delinquencies [5]. Market Reaction - Following the financial disclosures, Open Lending's share price plummeted by 57% to close at $1.17 on April 1, 2025 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Civitas Resources, Inc. for failing to disclose significant operational challenges during the Class Period from February 27, 2024, to February 24, 2025 [1][3]. Financial Performance - Civitas reported Q4 2024 revenue of $1.29 billion, missing consensus estimates by $3.44 million, and non-GAAP earnings per share of $1.78, which was $0.21 below expectations [4]. - The company’s net income for the quarter was $151.1 million, or $1.57 per share, a decline from $302.9 million, or $3.23 per share, in the same quarter the previous year [4]. Operational Challenges - The lawsuit claims that Civitas was likely to significantly reduce its oil production in 2025 due to declines after peak production at the DJ Basin in Q4 2024 [3]. - Civitas indicated that increasing oil production would necessitate acquiring additional acreage and implementing disruptive cost-reduction measures [3]. - The company announced a 10% workforce reduction and the termination of its Chief Operating Officer and Chief Transformation Officer [5]. Market Reaction - Following the announcement of its financial results and operational outlook, Civitas's stock price fell by $8.95, or 18%, closing at $40.35 per share on February 25, 2025 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for irregularities in financial reporting and practices related to its acquisition of Lugano Holdings, leading to a significant drop in stock price [1][3]. Group 1: Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut [2]. - In 2021, Compass acquired a majority interest in Lugano Holdings, Inc., a high-end jewelry designer, for an enterprise value of $256 million [2]. Group 2: Legal Action Details - The class action lawsuit pertains to investors who purchased Compass securities between May 1, 2024, and May 7, 2025 [1]. - Investors have until July 8, 2025, to seek appointment as lead plaintiff in the class action [2]. Group 3: Financial Irregularities - On May 7, 2025, Compass disclosed irregularities in Lugano's non-CODI financing, accounting, and inventory practices, necessitating a restatement of previously issued financial statements for 2024 [3]. - Following this announcement, Compass' stock price plummeted by $10.70 per share, a decline of over 62%, closing at $6.55 on May 8, 2025 [3].